Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab + R-CHOP in Untreated DLBCL
NCT04980222Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2022
- Primary completion
- Oct 2024
- Countries
- 6
01
Overview
A Phase 2 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Mar 2022; status: active, not recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04980222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04980222.